Theme

Post-Surgical Micronized Dienogest Yields 0% Endometriosis Recurrence and Near-Total Pain Elimination at 6 Months

Source
Источник: Проспективное одноцентровое открытое наблюдательное исследование клинической эффективности микронизированного диеногеста 2 мг (препарат Норметрилла) в комбинированном лечении эндометриоза.
0%
Endometriosis Recurrence

Confirmed clinically and via ultrasound at 6 months, achieved alongside complete regression of chronic pelvic pain, dysmenorrhea, and dyspareunia.

Study Architecture

Population

30 reproductive-age women (avg 32 ± 3.7y) with external genital endometriosis (deep infiltrative / endometrioid ovarian cysts).

Intervention

Laparoscopy (cyst/foci excision) + 2 mg continuous daily micronized dienogest (Normetrilla).

Duration

6 months. Prospective, single-center, open observational single-arm cohort.

Key Findings: Unprecedented Symptom & QoL Recovery

VAS Pain Severity Shift

By Month 6, all 30 patients reported pain intensity plummeting to 0–1 points.

EHP-5 Quality of Life Domains

Significant exponential drop (p < 0.001), indicating rapid psychosocial and mobility recovery.

High Tolerability Profile

6.7%
Discontinuation

Only 2/30 patients due to manageable mild AEs (acne, calf pain).

40%
Expected Bleeding

12/30 experienced abnormal uterine bleeding; none required stopping therapy.

Standard of Care Recommendation

For practicing gynecologists and surgeons, immediate postoperative initiation of 2 mg continuous micronized dienogest is strongly recommended following laparoscopic surgery for endometriosis.

This combined surgical-pharmacological approach acts as a powerful prophylactic shield against short-term recurrence while safely delivering rapid, comprehensive symptom relief.

AbbreviationsQuick
ВАШ — визуальная аналоговая шкала; РОАГ — Российское общество акушеров-гинекологов; УЗИ — ультразвуковое исследование; EHP-5 — Endometriosis Health Profile – 5; ESHRE — European Society of Human Reproduction and Embryology.
Bibliography3
  1. Сонова М.М., Карапетян Э.А., Арсланян К.Н. и др. Клиническая эффективность микронизированного диеногеста в комбинированном лечении эндометриоза. Эффективная фармакотерапия. 2026; 22 (2): 6–10. (DOI: 10.33978/2307-3586-2026-22-2-6-10)
  2. Becker C.M., Bokor A., Heikinheimo O., et al. ESHRE guideline: endometriosis. Hum. Reprod. Open. 2022; 2022 (2): hoac009.
  3. Сухих Г.Т., Серов В.Н., Адамян Л.В. и др. Алгоритмы ведения пациенток с эндометриозом: согласованная позиция экспертов Российского общества акушеров-гинекологов. Акушерство и гинекология. 2023; 5: 159–176.